(London) The US government is investing nearly half a billion dollars in the development and large-scale distribution of a treatment for COVID-19 from the British laboratory AstraZeneca, in late-stage testing clinics, the pharmaceutical giant said in a statement Monday. .
Posted Oct 12, 2020 at 9:42 am
With an investment of $ 486 million, the US government will contribute to the development and distribution of 100,000 doses by the end of 2020 and possibly an additional million by 2021, he says.
"The AZD7442 antibody combination is progressing rapidly in phase 3 studies," adds the group.
Two studies "in the United States and elsewhere" will enroll "6,000 adults for the prevention of COVID-19 disease and additional studies in approximately 4,000 adults will target the treatment of infections" by the novel coronavirus, explains from. -he.
The pharmaceutical group, which is developing a 'vaccine candidate' in parallel with the University of Oxford, which is considered one of the most promising, announced in late August that it had started phase 1 trials with the drug AZD7442, which was already funded. for a fee of $ 25 million from the US government.
The drug AZD7442 is a combination of two long-lasting antibodies derived from recovering COVID-19 patients, discovered by the Vanderbilt University US Medical Center and approved by AstraZeneca in June.